Protocols for Melanoma
| HIC 0807004008 Mario Sznol M.D. CA 184-029: Adjuvant Immunotherapy with Anti-CTLA-4 Monoclonal Antibody (Ipilimumab) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma: A Randomized, Doubleblind Phase 3 trial of the EORTC Melanoma Group |
| HIC 0811004469 Harriet Kluger M.D. Phase III Randomized Study of Four Weeks High Dose IFN-a2b in Stage T2b No, T3a-bN0, T4a-b No, and T1-4, N1a, 2a (microscopic) Melanoma (ECOG 1697) |